



25-6 1617

Patent Application
Attorney Docket No. PC22013AADO

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of April 2005.

By

Madeline Deveran

(Signature of person mailing)
Madeline Deveran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Alasdair Mark Naylor, et al. :

APPLICATION NO.: 10/017,273 : Examiner: San Ming R. Hui

FILING DATE: December 12, 2001 : Group Art Unit: 1617

TITLE: TREATMENT OF MALE SEXUAL :
DYSFUNCTION

Mail Stop Amendment
Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.


Respectfully submitted,

Date:


April 7, 2005

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC22013AADO				SERIAL NO. 10/017,273					
				APPLICANT Alasdair Mark Naylor, et al.									
				FILING DATE December 12, 2001				GROUP 1617					
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Berglund, et al., "Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide receptor subtypes ¹ , <u>Society for Experimental Biology and Medicine</u> , pp. 217-244, (2003)											
		Burchardt, et al., "Hypertension is Associated with Severe Erectile Dysfunction", <u>The Journal of Urology</u> , Vol. 164, pp. 1188-1191, (2000)											
		Cellek, et al., "Nitrgic control of peripheral sympathetic responses in the human corpus cavernosum: A comparison with other species", <u>Pharmacology</u> , Vol. 94, pp. 8226-8231, (1997)											
		Hedlund, et al., "Effects of some peptides on isolated human penile erectile tissue and cavernous artery", <u>Acta Physiol Scan</u> , Vol. 124, pp. 413-419, (1985)											
		Kirkeby, et al., "Neuropeptide Y (NPY) In Human Penile Corpus Cavernosum Tissue and Circumflex Veins-Occurrence and In Vitro Effects", <u>The Journal of Urology</u> , Vol. 145, pp. 605-609, (1991)											
		Ledda, et al., "Diabetes, Hypertension and Erectile Dysfunction", <u>Current Medical Research and Opinion</u> , Vol. 16, Suppl. 1, pp. s17-s20, (2000)											
		Mieczyslaw et al., "Increased blood pressure response in europeptide Y transgenic rats", <u>American Journal of Physiol Regulatory Integrative Comp Physio</u> , Vol 281, pp. R417-R426, (2001)											
		Mikhailidis, et al., "The treatment of Hypertension in Patients with Erectile dysfunction", <u>Current Medical Research and Opinion</u> , (Vol. 16, pp. s31-s36, (2000)											
		Mizusawa, et al, "Morphological and functional in vitro and in vivo character corpus cavernosum", <u>British Journal Pharmacol</u> , Vol. 132 (6), pp. 1333-41, (2001)											
		Smyth, et al, "Cotransmission from sympathetic vasoconstrictor neurons: differences in guinea-pig mesenteric artery and vein", <u>Autonomic Neuroscience: Basic & Clinical</u> , Vol. 86, pp. 18-29, (2000)											
		Thiele, et al, "Ethanol consumption and resistance are inversely related to neuropeptide Y levels", <u>Nature</u> , Vol. 396, pp. 366-369, (1998)											
		Thorsell, et al, "Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression", <u>PNAS</u> , Vol. 97, pp. 12852-12857, (2000)											
		Tong, et al, "The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat", <u>Journal of the Autonomic Nervous System</u> , Vol. 56, pp. 215-218, (1996)											



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC22013AAD0		SERIAL NO. 10/017,273	
		APPLICANT Alasdair Mark Naylor, et al.			
		FILING DATE December 12, 2001		GROUP 1617	
		Wespes, et al, "Study of neuropeptide Y-containing nerve fibers in the human penis", <u>Cell and Tissue Research</u> , Vol. 254, pp. 69-74, (1998)			
EXAMINER		DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE